Publicacions en què col·labora amb MARTINA STEINER (24)

2024

  1. An Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis

    Journal of Clinical Medicine, Vol. 13, Núm. 5

  2. Impact of systemic therapies on SARS-CoV-2 antibody seroprevalence in patients with immune-mediated diseases

    Medicina Clinica, Vol. 162, Núm. 10, pp. 470-476

  3. Raynaud's phenomenon and digital ischaemia induced by ixekizumab

    Rheumatology (Oxford, England), Vol. 63, Núm. 1

2023

  1. AB1352 Impact of Systemic Therapies on the Seroprevalence of Sars-Cov-2 in Patients with Immune-Mediated Diseases

    Annals of the Rheumatic Diseases, Vol. 82, Núm. Suppl 1, pp. 1907.1-1907

  2. POS0793-HPR Observational Study in Real Clinical Practice of the Treatment of Non-Infectious Uveitis

    Annals of the Rheumatic Diseases, Vol. 82, Núm. Suppl 1, pp. 689.2-690

  3. Seroprevalence of SARS-CoV-2 antibodies in patients with immune-mediated inflammatory diseases treated with biological and synthetic targeted therapies

    Revista Chilena de Infectologia, Vol. 40, Núm. 6, pp. 618-625

  4. The Real-World Study of Immunogenicity and Safety of the Adjuvant Recombinant Vaccine against Varicella Zoster Virus in Patients with Immune-Mediated Inflammatory Diseases Treated with Janus Kinase Inhibitors

    Vaccines, Vol. 11, Núm. 10

2022

  1. Incidence of COVID-19 in 902 Patients With Immunomediated Inflammatory Diseases Treated With Biologics and Targeted Synthetic Disease-Modifying Antirheumatic Drugs-Findings From the BIOCOVID Study

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, Vol. 28, Núm. 2, pp. e348-e352

  2. Incidence of COVID-19 in 902 Patients With Immunomediated Inflammatory Diseases Treated With Biologics and Targeted Synthetic Disease-Modifying Antirheumatic Drugs—Findings From the BIOCOVID Study

    JCR: Journal of Clinical Rheumatology, Vol. 28, Núm. 2, pp. e348-e352

2021

  1. Impact of biological therapies on the immune response after pneumococcal vaccination in patients with autoimmune inflammatory diseases

    Vaccines, Vol. 9, Núm. 3, pp. 1-12

  2. Measuring Choroid Thickness as a Marker of Systemic Inflammation in Patients with Ankylosing Spondylitis

    Journal of Clinical Rheumatology, Vol. 27, Núm. 8, pp. E307-E311

  3. Protocolised odontological assessment of patients with primary Sjögren's syndrome

    Reumatologia Clinica, Vol. 17, Núm. 1, pp. 25-31

  4. Reply

    Medicina Clinica

  5. Serological response to influenza vaccine in patients with autoimmune inflammatory diseases: Results of RIER study

    Medicina Clinica, Vol. 156, Núm. 3, pp. 118-122

2020

  1. Choroidal Thickness Is a Biomarker Associated With Response to Treatment in Ankylosing Spondylitis

    JCR: Journal of Clinical Rheumatology

  2. Evaluation of the immune response to hepatitis B vaccine in patients on biological therapy: results of the RIER cohort study

    Clinical Rheumatology, Vol. 39, Núm. 9, pp. 2751-2756

  3. Reproducibilidad de la medición manual del grosor coroideo utilizando la tomografía de coherencia óptica

    Archivos de la Sociedad Española de Oftalmologia, Vol. 95, Núm. 8, pp. 379-385

2019

  1. Antibody responses to influenza vaccine in patients on biological therapy: Results of RIER cohort study

    Medicina Clinica, Vol. 153, Núm. 10, pp. 380-386

  2. Choroidal and retinal thickness in systemic autoimmune and inflammatory diseases: A review

    Survey of Ophthalmology, Vol. 64, Núm. 6, pp. 757-769

  3. Spanish Registry of Recent-onset Psoriatic Arthritis (REAPSER study): Aims and methodology

    Reumatologia Clinica, Vol. 15, Núm. 5, pp. 252-257